An interventional study of Lobectomy-First and Lymphadenectomy-First in Non Small Cell Lung Cancer, sponsored by Sun Yat-sen University. Active, not recruiting at 26 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
During the surgery for non-small cell lung cancer (NSCLC), lymphadenectomy or lobectomy are performed first, different surgeons have different choices. Oncology textbooks require dissecting distant lymph nodes (LNs) first and then dissecting nearby LNs. According to this requirement, thoracic surgeons should first perform lymphadenectomy and then lobectomy. Unfortunately, there is no high-level evidence to prove which surgical sequence is more beneficial to the long-term survival of NSCLC patients. In this multi-center randomized controlled trial (RCT), patients with stage I-II NSCLC were enrolled as the research object to determine which surgical sequence (lymphadenectomy-first vs. lobectomy-first) is better for the short-term and long-term outcomes in NSCLC patients.
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 620 is above the median of 62 across 5,213 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with operable NSCLC received lobectomy first then received lymphadenectomy for surgical treatment.
Procedure: Lobectomy-First
Patients with operable NSCLC received lymphadenectomy first then received lobectomy for surgical treatment.
Procedure: Lymphadenectomy-First
During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lobectomy first, and then perform lymphadenectomy next.
During the surgical treatment for patients with NSCLC, thoracic surgeons should perform lymphadenectomy first, and then perform lobectomy next.
5-year disease-free survival (DFS)
The disease-free survival rate 5 years after surgery
Time frame: 5 years after surgery
5-year overall survival (OS)
The overall survival rate 5 years after surgery
Time frame: 5 years after surgery
3-year disease free survival (DFS)
The disease-free survival rate 3 years after surgery
Time frame: 3 years after surgery
3-year overall survival (OS)
The overall survival rate 3 years after surgery
Time frame: 3 years after surgery
Intraoperative blood loss
Total blood loss during the surgery
Time frame: During the surgery
Conversion rate
The number of cases converted to thoracotomy in a group divided by the total number of included cases in this group
Time frame: During the surgery
Perioperative complications rate
The number of cases in a group with perioperative complications divided by the total number of included cases in this group
Time frame: The day of surgery, 2/4/8/12/26/52 weeks after surgery
Operative death rate
The number of cases in a group died within 30/90 days after surgery divided by the total number of cases in this group
Time frame: 30/90 days after surgery
Postoperative hospital stays
The number of days between the date of surgery and the date of discharge
Time frame: Between the date of surgery and the date of discharge, assessed up to 30 days
Postoperative pain score
The degree of pain after surgery was measured using Numerical Rating Scale (NRS). The patient is asked to make three pain ratings, corresponding to current, best and worst pain experienced over the past 24 hours on a scale of 0 (no pain) to 10 (worst pain imaginable). The average of the 3 ratings was used to represent the patient's level of pain over the previous 24 hours
Time frame: Daily after surgery for up to 7 days and at weeks 2/4/8/12/26/52 after discharge
R0 rate
The number of cases in a group received complete resection divided by the total number of cases in this group
Time frame: Postoperative in-hospital stay up to 30 days
Operative time
The total time from skin to skin and the time of each step
Time frame: During the surgery
Chest tube duration
The number of days between the date of surgery and the date of chest tube removal
Time frame: Postoperative in-hospital stay up to 30 days
The numbers of circulating tumor cell (CTC)/circulating tumor DNA (ctDNA) before and after operation
3ml of peripheral arterial blood was drawn before surgery and immediately after chest closure, and then CTC/ctDNA was isolated by differential centrifugation for quantitative measurement
Time frame: During the surgery
Acesodyne (Grade III) dose
The total amount of morphine used by the patient during the postoperative hospital period
Time frame: Postoperative in-hospital stay up to 30 days
Total cost of hospitalization
The total medical cost of the patient from admission to discharge
Time frame: From the date of admission to the date of discharge, assessed up to 30 days
The number of resected lymph nodes
The number of resected lymph nodes were calculated according to the official pathological report after surgery
Time frame: Postoperative in-hospital stay up to 30 days
Plan to share: No
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Sun Yat-sen University